News
NKTX
2.660
+7.69%
0.190
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
TipRanks · 4d ago
Weekly Report: what happened at NKTX last week (0810-0814)?
Weekly Report · 5d ago
Nkarta price target lowered to $10 from $11 at Stifel
TipRanks · 5d ago
Nkarta Is Maintained at Buy by Stifel
Dow Jones · 08/14 12:34
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
TipRanks · 08/14 11:40
Nkarta Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.
Dow Jones · 08/11 12:45
Nkarta Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/11 12:45
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
Benzinga · 08/11 12:34
Nkarta: Buy Rating Reiterated with Unchanged $11 Price Target on Solid Cash Runway and Advancing Trials
TipRanks · 08/11 11:06
Nkarta price target lowered to $14 from $16 at H.C. Wainwright
TipRanks · 08/11 10:10
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)
TipRanks · 08/11 06:50
Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019
NASDAQ · 08/11 05:57
Nkarta reports Q2 EPS (54c), consensus (36c)
TipRanks · 08/10 21:25
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Benzinga · 08/10 21:04
Nkarta GAAP EPS of -$0.54 misses by $0.16
Seeking Alpha · 08/10 21:04
*Nkarta: Expects Current Cash and Cash Equivalents to Fund Its Current Operating Plan Into 2029 >NKTX
Dow Jones · 08/10 20:39
Weekly Report: what happened at NKTX last week (0803-0807)?
Weekly Report · 08/10 10:16
Weekly Report: what happened at NKTX last week (0727-0731)?
Weekly Report · 08/03 10:15
Weekly Report: what happened at NKTX last week (0720-0724)?
Weekly Report · 07/27 10:20
Weekly Report: what happened at NKTX last week (0713-0717)?
Weekly Report · 07/20 10:16
More
Webull provides a variety of real-time NKTX stock news. You can receive the latest news about Nkarta, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.